3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
8
Neoplasms
3
Hemangioma, Capillary
2
Anxiety Disorders
2
Weight Loss
1
Vomiting
1
Urinary Incontinence, Stress
1
Urinary Incontinence
1
Urinary Bladder Neoplasms
1
Shoulder Pain
1
Respiratory Aspiration
1
Psychomotor Agitation
1
Prostatic Neoplasms
1
Premature Birth
1
Polycystic Ovary Syndrome
1
Pediatric Obesity
1
Pancreatic Neoplasms
1
Pain, Postoperative
1
Ovarian Cysts
1
Obesity
1
Neuromuscular Diseases
1
Neuroblastoma
1
Nasopharyngeal Carcinoma
1
Myofibroma
1
Myelodysplastic Syndromes
1
Myasthenia Gravis
1
Multiple Myeloma
1
Menstruation Disturbances
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Interventions
Cisplatin
104
Radiotherapy, Intensity-Modulated
59
Gemcitabine
53
toripalimab
35
Fluorouracil
30
Docetaxel
30
Capecitabine
28
Radiotherapy
23
Drug Therapy
20
camrelizumab
19
nimotuzumab
16
nedaplatin
12
Chemoradiotherapy
12
sintilimab
11
apatinib
11
Induction Chemotherapy
11
Immune Checkpoint Inhibitors
11
spartalizumab
10
endostar protein
8
Paclitaxel
8
Cetuximab
8
tislelizumab
7
pembrolizumab
7
Endostatins
7
Bevacizumab
7
anlotinib
6
Radiation
6
Endoscopy
6
fludarabine
5
S 1 (combination)
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Nasopharyngeal Carcinoma
×
Population Groups
×
Clear all
NCT01536223
2013-03-05
ESNCCT
Zhejiang Cancer Hospital
Phase 3
Unknown
400 enrolled